Get started

Biotech

CBDT -- Symmetrical Triangle breakout on REXALL partnership newsSymmetrical Triangle breakout. Bullish MACD cross. Likely gap up tomorrow after major news today: Empower Partners with Rexall(R) To Launch Integrated Healthcare Centres Partnership Accelerates Empower's Strategy To Execute National Healthcare Centre Expansion By Bringing Accessible and Progressive Primary Care and Para-Medical Care to Millions of Canadians VANCOUVER, BC / ACCESSWIRE / February 9, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) ("Empower" or the "Company") an integrated healthcare company serving patients through medical centres, telemedicine platforms, operating a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce effective February 8, 2021 a partnership with Rexall Pharmacy Group to launch the first of multiple integrated healthcare centres within Rexall pharmacies commencing in Ontario, Canada. "In our first press release of 2021 announcing the closing of our Canadian Clinics acquisition, I stated Empower had a winning business model with immediate expansion plans throughout Greater Toronto, followed by Ontario and then nationwide with at least 30 clinics in rapid succession. Empower is proud to begin delivering on that promise." said Steven McAuley, Chairman & CEO. "To say this is the Company's biggest announcement in its history would not be an over statement. This partnership with Rexall accelerates our nationwide healthcare expansion strategy, I look forward to bringing Six Sigma philosophies and continuous process improvements to our operations to ensure customers and our patients have access to our primary care and para-medical services for years to come. Today marks a major win for Canadian healthcare and the shareholders of Empower Clinics." PARTNERSHIP IDENTIFIES INITIAL LOCATIONS IN ONTARIO Rexall and Empower have identified numerous initial locations throughout Ontario, spanning from Ottawa to London and around the GTA. The size of the locations can range from 1,500 to 4,000 square feet. As each new location is agreed upon, key terms are outlined in a letter of intent and in the lease or sub-lease agreements with the first anticipated agreements February 2021. HEALTH CARE SERVICES TO BE DELIVERED Empower will be opening primary care, plus para-medical healthcare services in each of the locations, with a target of four (4) to six (6) Medical Doctors (MD) and four (4) to six (6) paramedical practitioners per location. Primary care services include: Family physicians Walk-in physicians Tele-medicine and virtual care Paramedical services include: Chiropractic Physiotherapy Registered Massage Therapy Chiropody Acupuncturists Osteopaths Nutritionists ADDITIONAL HEALTH CARE SERVICES EXPECTED TO BE ADDED Given the anticipated expansion and penetration of Empower Clinics into the Canadian market, the Company intends to continue adding valuable specialized medical services to strengthen the quality of healthcare at each location that can include: Dermatology Cardiology Empower is currently in advanced discussions with potential partners in each of these specialty areas and believes they hold the potential to add significant value to the operations of each healthcare centre. This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management agoracom.com
C
by wealth_bakery
3
$ZOM Increases Bought Deal Offering of Common Shares to $173.5 MZomedica Corp. Increases Previously Announced Bought Deal Offering of Common Shares to $173.5 Million. today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 91,315,790 common shares of Zomedica, at a price to the public of $1.90 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 11, 2021, subject to satisfaction of customary closing conditions. finance.yahoo.com
AMEX:ZOM
by AlenCiken
2
$OTLK Secures Funding to Support ONS-5010 / LYTENAVA™Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $35.0 Million announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 35,000,000 shares of common stock of Outlook Therapeutics, at a price to the public of $1.00 per share, less underwriting discounts and commissions. finance.yahoo.com Outlook Therapeutics Announces Closing of $35.0 Million Bought Deal finance.yahoo.com Outlook Therapeutics’ Recent Financing Secures Funding to Support ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Through Planned BLA Submission The combined net proceeds from these stock offerings are expected to provide sufficient capital to fund operations through the expected filing of the Biologics License Application (BLA) for ONS-5010 for wet age-related macular degeneration (wet AMD), which is planned for the end of calendar 2021 . “Not only have we secured enough capital to significantly extend our cash runway through important upcoming milestones in 2021, but we have provided ourselves with more time to unlock the greatest value and potential for ONS-5010, the company, and our stockholders. We believe we are now in an improved position that will allow us to both maximize the value of this asset and to provide an FDA-approved ophthalmic formulation of bevacizumab to patients .” Extensive market research indicates that ONS-5010, if approved, will be a significant therapy in the retinal anti-VEGF market, currently estimated to be in excess of $13 billion worldwide. Clinical Progress of ONS-5010 On Track - Therapeutics expects to report pivotal safety and efficacy data in the third calendar quarter of 2021. finance.yahoo.com
NASDAQ:OTLK
by AlenCiken
$OCGN Skyrockets On $23M Capital Raise Issued On 46% PremiumOcugen Inc. Announces $23 Million Registered Direct Offering of Common Stock Priced at a Premium to Market. today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the sale of an aggregate of 3,000,000 shares of its common stock at a purchase price of $7.65 per share in a registered direct offering. The offering is expected to close on or about February 10, 2021, subject to the satisfaction of customary closing conditions. The gross proceeds of the offering are expected to be approximately $23 million, prior to deducting placement agent’s fees and other offering expenses payable by Ocugen. Ocugen intends to use the net proceeds from the offering for general corporate purposes, capital expenditures, working capital and general and administrative expenses. finance.yahoo.com
NASDAQ:OCGN
by AlenCiken
7
$ZOM could surge 100% due to upcoming launch of TruformaTangible catalyst behind surge is due to the upcoming launch of Truforma , Zomedica’s point-of-care (POC) diagnostic device for the detection of thyroid disease in dogs and cats and adrenal disease in dogs. The platform will hit the market on March 30 , and ahead of the product’s debut, the company has also just nabbed a vital distribution deal. Last week, Zomedica announced an agreement with Miller Veterinary Supply who will distribute Truforma. Miller is the U.S.’s oldest wholesale veterinary distributor and one of the veterinary industry’s fastest growing businesses. The company will be Zomedica’s representative in the eastern and mid-eastern states. Its sales and customer service efforts will be bolstered by sales representatives assigned by Zomedica, which the company is currently recruiting as it prepares for the launch. The pet market has been a prime beneficiary of the pandemic’s stay-at-home mandates and according to the American Pet Products Association, spending in the segment reached a record $99 billion in the U.S. last year. Outlay on diagnostic care in this market is expected to grow to $2.8 billion in 2024 from $1.7 billion in 2019. H.C. Wainwright analyst Swayampakula Ramakanth says that ahead of Truforma’s debut, the agreement “strengthens the commercial machinery.” “We are encouraged by the progress in commercial preparation for the upcoming launch, and accordingly we are raising the probability of launch to 90%, up from 75% previously,” the 5-star analyst said. “Additionally, due to the lower yield of the long-term Treasury note that has resulted in a lower risk-free rate and a lower market risk premium, we have adjusted the discount rate to 6% from 12%.” To this end, Ramakanth boosted his price target on ZOM from $0.3 to $1.2, suggesting upside of an additional 20% from current levels. Needless to say, Ramakanth’s rating stays a Buy. finance.yahoo.com
AMEX:ZOM
by AlenCiken
Great tradeLets move to stocks, wolves🔥 Today we symmetrical triangle on BIM (Biomerieux) biotechnological company, which locates in Marcy-l'Étoile, France. There was a huge bullish sentiment before and now it has opportunity to grow. According to Elliott Waves theory it approached to wave D and looking to go to wave E. However it may become circumcised and break in coming future. So, lets follow the chart and look for the breakout point carefully. If you enjoy my FREE Technical Analysis , support the idea with a big LIKE👍 and don't forget to SUBSCRIBE my channel, you won't miss anything! Feel free to leave comments✉️
EURONEXT:BIM
by Berzerk_invest
OCGN and Bharat Biote Announce Execution of Definitive AgreementOcugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market. Definitive Agreement provides details of the previously announced intent to co-develop COVAXIN™ for the US market. Ocugen and Bharat Biotech to share US commercialization profits. Ocugen to receive initial supply of COVAXIN™ doses from Bharat Biotech upon authorization from US regulatory authorities while it ramps up manufacturing in the US. COVAXIN™ received EUA (Emergency Use Authorization) in India in January and is currently in a fully enrolled Phase 3 clinical trial involving 25,800 patients. COVAXIN™ (whole-virion inactivated COVID-19 vaccine candidate) effectively neutralizes UK variant of SARS-Cov-2 reducing the possibility of mutant virus escape. today announced they have entered into a definitive agreement to co-develop, supply, and commercialize Bharat Biotech’s COVAXIN™ , an advanced stage whole-virion inactivated COVID-19 vaccine candidate, for the United States market. Ocugen will have US rights to the vaccine candidate and will be responsible for clinical development , regulatory approval (including EUA) and commercialization for the US market . B harat Biotech will supply initial dose s to be used in the US upon Ocugen’s receipt of an EUA. In addition, Bharat Biotech will support the technology transfer for manufacturing in the US . In consideration for the exclusive license to the US market, Ocugen will share the profits from the sale of COVAXIN™ in the US market with Bharat Biotech, with Ocugen retaining 45% of the profits. In preparation for the development of COVAXIN™ in the US, Ocugen’s Vaccine Scientific Advisory Board and Ocugen management have initiated discussions with the U.S. Food & Drug Administration (FDA) and the Biomedical Advanced Research and Development Authority (BARDA) to develop a regulatory path to EUA and, eventually, biologics license application (BLA) approval in the US market for COVAXIN™. Ocugen is also in active discussions with manufacturers in the US to produce a significant number of doses of COVAXIN™ to support its US immunization program. H.C. Wainwright analyst Swayampakula Ramakanth raised his rating on Ocugen's stock on Thursday from neutral to buy and placed a $4.50 price forecast on its shares. Ramakanth cheered Ocugen's recent deal with India-based vaccine developer Bharat Biotech to potentially bring Covaxin, a COVID-19 vaccine candidate, to the U.S. market. Ramakanth posits that Covaxin could induce broader immunity and better protection against new coronavirus strains than the COVID-19 vaccines that have received emergency use authorization in the U.S. He also highlighted Covaxin's potential logistical advantages, due to its less onerous temperature storage requirements. Roth Capital analyst Zegbeh Jallah, meanwhile, believes Ocugen's share price could rise to as high as $8. Jallah applauded the structure of the deal, which gave Ocugen a 45% share of the potential profits from Covaxin's U.S. sales without requiring it to make an upfront payment to Bharat Biotech . Jallah's price target represents potential gains for investors of roughly 52% from Ocugen's closing price on Friday. Much of Ocugen's future growth prospects now rest on its ability to obtain emergency use authorization for Covaxin in the U.S . Thus, investors should brace for volatility in Ocugen's stock price as it advances toward clinical trials.
NASDAQ:OCGN
by AlenCiken
4
Vistagen (VTGN): Long-term Game-changer* This is not financial advice. This is my non-expert opinion. * Vistagen ( NASDAQ:VTGN ) is a clinical stage biopharmaceutical company with long-term potential. I believe it's technology is similarly game-changing the way I believe NanoFlu for Novavax is (www.novavax.com) ( ). It could have positive outcomes for the world. I hope that their tech comes to fruition. Their pipeline includes Neuroactive nasal sprays that don't involve benzodiazepine and its associated side effects. I hope they succeed because it could change the way patients with anxiety or depression-related disorders are treated. Vistagen: www.vistagen.com Pipeline: www.vistagen.com PH94B Neuroactive Nasal Spray is their most advanced candidate, which is currently in Stage 3 clinical trials. I encourage anyone who wants to do their own research. This animated demonstration was very informative for me www.youtube.com Keep an eye out for this company.
NASDAQ:VTGNLong
by traderman001
23andMe to Merge with Virgin Group's VG Acquisition Corp. SPAC23andMe to Merge with Virgin Group's VG Acquisition Corp. to Become Publicly-Traded Company Set to Revolutionize Personalized Healthcare and Therapeutic Development through Human Genetics. - 23andMe is a leading consumer genetics and research company that offers a personalized health and wellness experience, and has built a premier genetic database to unlock insights leading to the rapid discovery of promising new targets for drug development - Transaction will provide the capital to fund additional investment in key growth initiatives across 23andMe's consumer health and therapeutics businesses - The transaction will value the outstanding shares of capital stock of 23andMe at an aggregate enterprise value of approximately $3.5 billion - 23andMe CEO and Co-Founder Anne Wojcicki and Virgin Group's Sir Richard Branson are each investing $25 million into the $250 million PIPE and are joined by leading institutional investors including Fidelity Management & Research Company LLC, Altimeter Capital, Casdin Capital and Foresite Capital - The pro forma cash balance of the combined company will exceed $900 million at closing Completion of the transaction, estimated in the second calendar quarter of 2021. 23andMe is the only consumer genetic testing company with multiple FDA clearances for over-the-counter health and carrier status reports. 23andMe's existing equity holders will roll 100% of their equity into the combined company. Assuming no public shareholders of VG Acquisition Corp. exercise their redemption rights, 23andMe will be capitalized with up to $984 million in cash to fund operations and support new and existing growth initiatives. finance.yahoo.com
V
by AlenCiken
Sympathy playSympathy play Anavex stock gained after favorable data from Cassava Sciences in Alzheimer’s! With a rise yesterday, Cassava Sciences extended its gains after announcement of favorable data from an open-label study in Alzheimer’s disease! The shares have been on a bullish mode for the last several days, reaching an all-time high, on encouraging data for its differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders such as Alzheimer's disease, Parkinson's disease, Rett syndrome, and other central nervous system diseases.
NASDAQ:AVXL
by AlenCiken
2
“Strong Buy” Penny Stock With Over 200% Upside on the Horizon“Strong Buy” Penny Stock With Over 200% Upside on the Horizon a biotechnology company with a focus on the treatment of glioblastomas, a class of aggressive tumors that attack the braid and spinal cord. These cancers, while rare, are almost always terminal, and CNS is working a new therapy designed to more effectively cross the blood-brain barrier to attack glioblastoma. Berubicin, CNS’s flagship drug candidate, is an anthracycline, a potent class of chemotherapy drugs derived from the Streptomyces bacteria strains, and used in the treatment of a wide variety of cancers. Berubicin is the first drug in this class to show promise against glioblastoma cancers. The drug candidate has completed its Phase 1 clinical trial, in which 44% of patients showed a clinical response. This number included one patient who showed a ‘Durable Complete Response,’ defined as a demonstrated lack of detectable cancer. Following the success of the Phase 1 study, CNS applied for, and received, FDA approval of its Investigational New Drug application. This gives the company the go-ahead to conduct a Phase 2 study on adult patients, an important next step in the development of the drug. CNS plans to start the mid-stage trial in 1Q21. Based on the potential of the company’s asset in glioblastoma, and with its share price at $2.22, several analysts believe that now is the time to buy. Among the bulls is Brookline’s 5-star analyst Kumaraguru Raja who takes a bullish stance on CNSP shares. Berubicin is the first anthracycline to cross the blood-brain barrier in adults and access brain tumors… Berubicin has promising clinical data in a Phase 1 trial in recurrent glioblastoma (rGBM) and has Orphan drug designation for treatment of malignant gliomas from the FDA. We model approval of Berubicin for treatment of recurrent glioblastoma in 2025 based on the Phase 2 data with 55% probability of success for approval. We model peak sales of $533 million in 2032,” Raja opined. “CNS pipeline also includes WP1244 (novel DNA binding agent) that is 500x more potent than daunorubicin in inhibiting tumor cell proliferation is expected to enter the clinic in 2021… In vivo testing in orthotopic models of brain cancer showed high uptake of WP1244 by brain and subsequent antitumor activity,” the analyst added. finance.yahoo.com
NASDAQ:CNSP
by AlenCiken
2
Lexaria Provides Guidance on Upcoming R&DLexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering Lexaria also announced the pricing of an underwritten public offering (the "Offering") of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The shares of common stock and warrants comprising the units are immediately separable and will be issued separately, but will be purchased together. The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. The Company has granted the underwriter a 30-day option to purchase up to an additional 274,285 shares of common stock and/or warrants to purchase up to 274,285 shares of common stock. finance.yahoo.com Lexaria Provides Guidance on Upcoming R&D Lexaria recently closed an oversubscribed financing of US$11 million that has greatly enhanced the Company's ability to conduct applied R&D designed to evidence effectiveness of its patented DehydraTECHTM drug delivery technology across multiple classes of bioactive substances or drugs. In the weeks to come, Lexaria expects to announce many new studies designed to provide initial evidence expected to support further study and commercial exploitation. All studies referenced within this press release are fully funded from existing Company resources. finance.yahoo.com
NASDAQ:LEXX
by AlenCiken
TYME Granted U.S. Patent Claims Treat COVID-19 InfectionsTYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections TYME announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company’s metabolomic technology platform. The patent, U.S. Patent No. 10,905,698, is directed to methods for treating COVID-19. Unlike immune therapies that depend upon the structure of the external virus coat of COVID-19 where the therapy directs its attack, we believe TYME-19 is agnostic to this structure and any mutations to the viral coat. TYME intends to initiate the appropriate clinical trials to substantiate the safety and efficacy of TYME-19. TYME-19 is an investigational compound that is not approved in the U.S. for any disease indication. finance.yahoo.com
T
by AlenCiken
1
Will ARGX break out ascending channelWill Argenx be Wall streets next Biotech unicorn? I am extremely bullish! Biotech is booming business. Monoclonal antibodies are revolutionizing pharma industry. Again great news for Argenx. 01feb2021 launches new global offering to raise funds after 'Go' decisions for CIDP treatment trials www.argenx.com www.argenx.com 02feb2021 Argenx raises $1 bln www.argenx.com statement showing their product is might be much better than competitors www.argenx.com Products are yet to be approved by FDA. Current products that are currently in clinical trials are: Efgartigumod Phase 3 trials submitted for Mystenias gravis/MG (1.4 million patients worldwide) Phase 3 trials ongoing for Immune Thrombocytopenia/ITP (200 thousand patients worldwide) Phase 2 trials ongoing for Chronic inflammatory Demyelinating polyneuropathy/CIDP (300 thousand patients worldwide) Phase 2 trials ongoing for Pemphigus Vulgaris/PV (200 thousand patients worldwide) This products aims to treat over 2 million patients worldwide. IF this products proves to have a high enough efficacy Argenx wil immediately have hit the jackpot. Cusatuzumab (in cooperation with J&J) Phase 2 trials ongoing for Accute Myeloid Leukemia (AML) (incidence 4.3 to 100.000 and a death rate 2.8 to 100.000 which is extremely high) At some point in our life we all have been confronted with cancer. Sayings like 'it always has to happen to the best of us' don't exist for nu reason. Curing cancer isn't only a billion dollar quest(ion). It's a matter of life and death. Phase 2 trials ongoing for Higher-risk Myelodysplastic Syndromes (MDS) (approximate prevalence op 150 thousand people affected worldwide) Cusatuzumab again might work out to become a flagship product product for Argenx. Argenx pipeline products show immense promise. The company's market cap is still on the low side compared to other pharma companies with working products. Possible upside to be a multiple of the current market cap. Current market cap. $16.695bln as of 03feb2021 Compared to other biotech companies as of 03feb2021 Alexion Pharmaceuticals $33.84 bln Regeneron: $52.41 bln Vertex Pharmaceuticals $54.84 bln Novo Nordisk $167.60 bln If Argenx keeps doing great, FDA approves efgartigumod and stock price remains in this ascending channel Stock will double within 2 years time. ARGX might even break out above this channel coming days
NASDAQ:ARGXLong
by DrSkeletor
Why SELLAS Life Sciences Is Surging Premarket?Why SELLAS Life Sciences Is Surging Premarket? SELLAS Life Sciences is captivating investors thanks to its late-stage cancer vaccine Thanks to some news in December in the biopharma space, SLS stock is racing higher. So what was that news? And what else do you need to know? its leading candidate Galinpepimut-S is making its way through Phase 3. This immunotherapy targets the Wilms Tumor 1, which is the leading cancer antigen. Essentially, the company believes that this therapy, which is given via vaccine, reduces the immune response in a patient and has the ability to delay the relapse of cancer. Although SELLAS Life Sciences is testing it for a variety of cancers, it is currently in Phase 3 trials for acute myeloid leukemia. This lead candidate is where the massive move in SLS stock comes from. Importantly, SELLAS Life Sciences had some big news of its own in december. While its leading immunotherapy candidate remains in clinical trials, it entered a license agreement with China-based 3D Medicines. Through this deal, 3D Medicines will handle developing and commercializing Galinpepimut-S in mainland China, Hong Kong, Taiwan and Macau. According to a company press release, this could net $202 million in license fees for SELLAS. It also could bring an upfront payment of $7.5 million sometime this quarter. it looks like another company is responsible for the move in SLS stock. What do I mean? Well, in december we saw a major rally in Greenwich LifeSciences (NASDAQ:GLSI). Ahead of a conference, the company shared promising Phase 2b data on its breast cancer immunotherapy. Importantly, Greenwich LifeSciences is evaluating GP2 as a therapy for patients who have already undergone surgery for breast cancer. And according to the report yesterday, GP2 has reduced the recurrence rate of cancer in trial participants to 0%. How does this tie into SELLAS Life Sciences? Well, GP2 and Galinpepimut-S are both unique immunotherapies that rely on vaccination as a delivery method. Essentially, both treatments are cancer vaccines. Both treatments are also quite innovative, representing potential advancements in the realm of cancer care. This means that with a more than 2,000% rally from GLSI stock, many investors may be rooting for the same with SLS. Remember though, this is a tiny company that must continue to navigate clinical trials. Keep an eye on SLS stock, but proceed with caution.
NASDAQ:SLS
by AlenCiken
100% Survival Achieved in Osteosarcoma Lung MetastasesMoleculin Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model a preclinical study in animals demonstrated a potentially significant therapeutic benefit of Annamycin against metastatic osteosarcoma. Computerized tomography (CT) scans demonstrated that animals treated with Annamycin exhibited significant suppression of tumor growth and not a single death was observed in the treated animals, whereas significant tumor burden contributed to the rapid death of 90% of untreated animals. While the study continues, as of day 130, the survival rate for animals treated with Annamycin was 100%, compared with only 10% for untreated animals. Annamycin is a "next generation" anthracycline that has recently been shown in animal models to accumulate in the lungs at up to 34 times the level of doxorubicin, which may account for the 100% survival rate attained in this most recent osteosarcoma lung metastases study. Moleculin recently announced that the FDA has allowed the Company's request for investigational new drug (IND) status in order to study Annamycin for the treatment of soft tissue sarcoma metastasized to the lungs. In addition, the FDA granted Orphan Drug Designation for Annamycin for the treatment of soft tissue sarcomas. "We expect that one, and potentially two, clinical trials in sarcoma lung metastases should be up and running this year." finance.yahoo.com
NASDAQ:MBRX
by AlenCiken
ANVS401 Improves Cognitive and Functional Outcomes in StrokeAnnovis Bio's Lead Candidate ANVS401 Improves Cognitive and Functional Outcomes in Stroke Mice Study data showing that a combination treatment using the Company's lead candidate ANVS401 and pifithrin after stroke improved mice locomotor activity and cognitive function more so than treatment with just one or the other agent. While both treatments yielded improvements in locomotor and cognitive function, the combined ANVS401/PFT- treatment proved able to enhance stroke-induced endogenous neurogenesis and improve the functional recovery in stroke animals. The combined treatment also significantly improved cognitive function more than the single treatment with PFT- alone. finance.yahoo.com
A
by AlenCiken
Simufilam Improves Cognition and Behavior in Alzheimer’s DiseaseCassava Sciences’ Simufilam Improves Cognition and Behavior in Alzheimer’s Disease in Interim Analysis of Open-label Study - Patients’ Cognition Improved 1.6 Points on ADAS-Cog11 -a 10% mean improvement from baseline to month 6. - Patients’ Behavior Improved 1.3 Points on NPI, a 29% mean improvement from baseline to month 6. - Improvements Maintained at 6 Months - - Results Support Advancing Simufilam into Phase 3 Clinical Program Next Steps: Cassava Sciences believes today’s data and prior clinical results support advancing simufilam into a Phase 3 clinical program in Alzheimer’s disease. Initiation of a Phase 3 trial remains on schedule for 2nd half 2021. Cassava Sciences and the U.S. FDA recently concluded a successful end-of-phase 2 (EOP2) meeting for the simufilam drug development program. Details of the EOP2 meeting will be announced Q1 2021 after official FDA meeting minutes are finalized. finance.yahoo.com
NASDAQ:SAVA
by AlenCiken